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In 2007, the prevalence of Atopic Dermatitis had increased two to three-fold within the last three decades and affected 15-20% of 
young children (Buys, 2007). Current treatment includes the use of both steroid and emollient creams. Current suggestions for the order 
of application are contradictory. This study aims to examine the role of the order of application of treatments for Atopic Dermatitis 
(AD). Hairless mice (SKH-1) were induced to a mild AD flare-up using 2,4-dinitrochlorobenzene (DNCB) and treated with either 1%
hydrocortisone (Maximum Strength Cortizone 10 cream) alone, 1% hydrocortisone followed by Cetaphil (emollient), or Cetaphil 
followed by 1% hydrocortisone. We assessed the efficacy of the treatments by measuring: body weights, area scores, severity scores, 
and IgE levels. For all measurements, there were no statistically significant differences observed between the treatment groups or 




Atopic Dermatitis (AD) presents with several challenging symptoms to 
everyday life and to caretakers.  Studies have shown the growing 
importance of trying to find a treatment regimen that will decrease the 
negative effects of AD (Buys, 2007; Eichenfield et. al., 2014; & 
Watkins, J. 2015).  Without a cure for AD, it is only possible to treat the 
symptoms of AD with moisturizers and medicated creams. 
 Lawton discusses uncertainties that patient and health professionals 
have including whether an emollient or topical steroid should be applied 
first when treating AD (Lawton, 2014). There is research to support the 
underlying assumption that applying an emollient improves treatment 
with hydrocortisone compared to hydrocortisone alone (Turpeinen, 
1991).  
 Hydrocortisone is one of the most commonly used topical 
corticosteroids.  Topical steroids such as hydrocortisone are used in the 
treatment of a flare-up or worsening in AD symptoms (Watkins, 2015) 
and are usually applied daily (Leung, 1998).  AD is a complex disorder, 
making hydrocortisone’s mechanism of action difficult to determine 
completely.  Mehta et. al.’s (1998) proposed mechanism is seen in 
Figure 1.  Mehta et. al. (1998) proposed that after the DNA binding site 
of receptor is exposed, there are two ways that the mechanism will 
branch off.  This is a result of either the presence or absence of an 
inflammatory stimulus.  Unfortunately, there are still many unknowns 
about the way the inflammation affects the mechanism of protein 
alterations, making this one possible proposal for hydrocortisone’s mode 
of action.  Emollients act on the epidermis, creating an occlusive barrier 
and preventing water loss from the skin.  Creams are the most common 
delivery system for an emollient.  Creams are a topical formulation 
known for a two-phase treatment (emulsion); two immiscible liquids, 
one substance in the other (Lodén, 2003).  Cetaphil, according to Hon, 
Leung, and Barankin (2013) is a barrier cream that contains dimethicone, 
a water-repellent substance, that helps to protect the skin from irritants 
and repeated hydration.  
 Eichenfield et.al. (2014) defined a guideline that acute areas of AD 
are recommended to have once-daily application until the affected area 
has significantly improved or is less thick.  Buys (2007) looked at 
clinical trials and showed that topical corticosteroids (hydrocortisone in 
the experiment) are effective when used up to four weeks based on 
previous research (Lebwohl, 1999; Maloney et. al., 2002; Sears, Bailer, 
& Yeadon, 1997).  These clinical trials also show that in many cases 
symptoms may be controlled within a shorter treatment time (Buys, 
2007; Lebwohl, 1999; Maloney et. al., 2002; Sears, Bailer, & Yeadon, 
1997). 
 In the present study, we evaluated the hypothesis that the order of 
application of 1% hydrocortisone cream and Cetaphil (emollient) is 
significant to the treatment of AD in a two-week treatment period.  The 
effects of the orders were assessed using hairless mouse model of 2,4-




Animals.  Three-week-old male SKH-1 Elite mice were purchased from 
Charles River and all the procedures were performed in accordance with 
the Guide for the Care and Use of Laboratory Animals: Eighth Edition 
(National Research Council Committee for the Update of the Guide for 
the Care and Use of Laboratory, 2011).  Before the experiment started, 
the animals were acclimated for nine days.  The animals were housed in 
a temperature and humidity controlled (22°C) room with a 12-hour light 
and dark cycle.  The mice were also allowed free access to food and 
water throughout the experiment. 
Grouping.  Mice were randomly divided into four groups: control 
without treatment, hydrocortisone-treated group only, hydrocortisone 
applied first and after 30 minutes Cetaphil was applied, and emollient 
applied first and after 30 minutes hydrocortisone was applied.  When the 
Figure 1. Proposed mechanism of glucocorticoid (hydrocortisone) 
action (Mehta et. al., 2016). 
 
Journal of the South Carolina Academy of Science, [2018], 16 (1)  | 26 
Undergraduate Research Article 
mice were obtained, they were immediately weighed, ear punched (for 
identification), and were randomly selected for each cage (four mice in 
each cage, with one cage of five).  At the end of acclimation, the cage 
numbers were placed into a container and drawn at random to assign the 
treatment/no treatment that each of the cages would receive. 
Induction of AD.  Induction of AD was performed using DNCB, as 
previously described (Kim et al., 2014), with minor modification.  
DNCB was mixed in a solution of 1:4 acetone and olive oil, respectively, 
to make a 1% solution.  The solution was then placed on an adhesive 
gauze (clear spot Band-Aid).  The Band-Aids were placed on the lower 
back of the mice for 24-hour periods on days 10, 12, 17, and 19 of the 
study (Figure 2). 
Treatment.  Once the AD was induced, treatment began on day 20 
(Figure 2).  Hydrocortisone cream (Maximum Strength Cortizone 10 
cream) 0.9 grams was measured out using a scupula and scale.  
Hydrocortisone was applied to the back of the mice where the AD-like 
lesions were located.  Once applied the scupula was measured again to 
try to reduce the amount of loss of cream and maintain an average of 0.9 
grams of cream per mouse.  Combined treatments used both 
hydrocortisone and Cetaphil (emollient used, 0.9g of the cream was 
measured and applied) on the backs of mice.  The procedure for applying 
the creams to the backs were the same in all the treatments.  The 
combined treatments had a 30-minute wait time in between the 
application of the first and the second cream.  
Body Weight.  Body weights for each of the mice were observed at every 
bedding change, twice weekly.  Body weights were collected to observe 
the health of the mice and to see if there was any noticeable correlation 
when sensitized and treated. 
Area Scores.  The area scores were measured on the blood collection 
days (once a week following sensitization period).  While the mice were 
anesthetized, AD-like lesion size was measured.  Measurements were 
taken of the longest and widest dimensions of AD-like lesions. 
Severity scores.  Using a modified form of the EASI score as previously 
described by Hanifin (2001), the lesions of each mouse was scored on a 
scale of 0-3 for each of the following criteria: redness, scaling, and 
thickness.  After the sensitization, the mice were scored by two members 
of the research team every day for the span of the experiment.  The mean 
scores were taken from each day’s scores and the standard deviations 
were calculated. 
Blood Collection.  Blood collection began immediately after 
sensitization on day 20 with a week between each collection (Figure 2).  
On blood collection days, the mice were not treated.  Mice from each 
group were anesthetized and blood was collected via tail venipuncture.  
As blood pooled on the surface, it was collected in Capillary Blood 
Collection Tubes.  The serum was collected and then frozen at 4°C until 
further testing. 
ELISA.  An IgE ELISA was performed using the serum collected.  The 
ELISA test was conducted according to the ELISA kit instructions (BD 
Biosciences OptEIA Set Mouse IgE kit). 
Results  
 
Statistical Analysis.  GraphPad software (Prism, San Diego, CA, USA) 
was used to plot graphs. One-way and two-way analysis of variance 
(ANOVA) with Bonferroni’s post-tests were used to perform the 
statistical analyses of the data. 
 
Body Weight.  As seen in Figure 3, there is a steady increase in weight 
during the acclimation period (the first 3 data points) this indicates the 
mice were growing, as to be expected with young mice (3 weeks old).  
There was a slower increase during the sensitization period until the 
second week’s sensitizing that showed variation in the body weights at 
the end of the study. The body weights for the treatment phase climaxed 
on day 25 for the three treatment groups (the control dropped slightly) 
and continued to drop, while the control increased and leveled out for 
the last week of the experiment.  There was no significant difference in 
the weights of the mice from each group at any point during the 
experiment indicating that there is no correlation with the significance of 
the order. 
Area Scores.  The control, hydrocortisone only, and the Cetaphil and 
hydrocortisone group all showed a decrease in AD-like lesion area size 
throughout the study (Figure 4), whereas hydrocortisone and Cetaphil 
showed a decrease between the first two collection days and the last day 
showed a slight increase in the area score.  However, there were no 
statistically significant difference between the treatment groups in lesion 
area size throughout the experiment. 
 
Severity Scores.  Figure 5 shows the mean severity scores increased in 
all groups during the sensitization phase and continued to rise at the start 
of the treatment period.  Each group then had severity scores return to 
near zero by the end of the study.  There was no significant difference 
between the treatment groups. 
 
IgE ELISA.  As shown in Figure 6, IgE was significantly higher than 
control in the hydrocortisone only group on day 20 (p<0.01). When 
comparing between days in the treatment groups, neither the 
hydrocortisone followed by the Cetaphil or the Cetaphil followed by the 
hydrocortisone showed a significant reduction in IgE during the 
treatment period.  The control group showed a significant increase in IgE 
between day 20 and 27 (p<0.05) and a significant reduction between day 
27 and day 35 (p<0.01).  The hydrocortisone only group showed no 
significant difference between day 20 and 27 but there was a significant 
decrease between day 27 and day 35 (p<0.05).  This is likely due to such 
a high start value for the IgE levels for the hydrocortisone only group 
compared to the other groups.  Looking at Figure 6 there appears to be 
no significance in the order of application. 
 
Figure 2.  Timeline of the acclimation, sensitization, and 
treatment.  Mice acclimated days 1-9 and were given free access to 
food and water.  The mice were sensitized on days 10, 12, 17, & 
19 using 1% DNCB in a vehicle of 1:4 acetone and olive oil 
respectively, on Band-Aids.  Treatment began on day 20 and 
continued throughout the experiment followed by sacrifice on the 
35th day. 
Figure 3. Representation of the mean weights of the mice in each of 
the treatment groups. The brackets represent the standard deviation 
per treatment group. 
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There seems to be no significance to the order of application of 
hydrocortisone and Cetaphil when comparing weight, area, severity 
scores, and IgE production.  The hydrocortisone-Cetaphil combination 
treatment may be preventing an increase in IgE (that is seen in the 
control group on day 27), but there was no significant decrease in IgE in 
these treatment groups.  These results do not support the alternative 
hypothesis that the order of application is significant to the treatment of 
Atopic Dermatitis.  Clinically speaking this is not far from what some 
doctors already thought.  Smoker & Voegeli (2014) conducted a critical 
review looking at 27 recommendations for the order of application and 
the time intervals and found that there were two main treatment 
recommendations: topical steroid should be applied first, then wait 30 
minutes and apply the emollient or apply emollient first then wait 30 
minutes and apply the topical steroid.  Our data concurs that the order of 
the application is not significant.  Physicians should be able to tell the 
patient that the order of the application is not significant to the treatment 
efficacy; as much as different articles recommending that there is at least 
a 30-minute absorption wait time in between the two applications 
(Lawton, 2014).  From our data, the hydrocortisone and emollient 
compared to hydrocortisone shows that there is not a significant 
difference in the treatment regimens.   
 
Limitations of the experiment were ways to measure area scores, blood 
collection, and limited sample size. The area scores were difficult to 
measure because some of the mice had large scabs that made it difficult 
to measure the area affected.  The mice were small and only 100 μL of 
blood could safely be collected from the mice every seven days.  The 
experiment groups only had four mice, which produces a fairly small 
statistical power.   
 
Further investigation is necessary to add to the statistical power of the 
current study. Based on conclusions found in this experiment, future 
studies are needed to determine the optimum time in between the 
application.  Also, repeat the current study with the appropriate time 
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